CYP2D6 and psoriasis: However, tildrakizumab, an anti‐IL‐23 mAb, had no clinically relevant effect on the exposure of any CYP probe substrates tested in the cocktail study (S‐warfarin, midazolam, dextromethorphan [CYP2D6], omeprazole, and caffeine) in patients with moderate to severe psoriasis.36